ADHD

Attention-Deficit Hyperactivity Disorder - Shire to Stay on Top Despite Drug Safety Fears and Generic Competition

ADHD Library Library Home This article was published in Anti-Infectives Week, which you can subscribe to online.

Driven primarily by continued uptake of Shires market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shires Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.

Scope

This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.

Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.

Provides a global market snapshot by including sales analysis for leading ADHD brands outside the seven major markets.

Key conclusions are supported by key opinion leader comment.

Highlights of this title

The April 2009 launch of generic competition in the US will cause sales of Shires leading ADHD product, Adderall XR, to decline sharply. However, Datamonitor maintains the expectation that Shire will remain the dominant player in the ADHD market over the forecast period due to the company's broad portfolio of products.

Intuniv (guanfacine hydrochloride) represents Shires first venture into the non-stimulant segment of the ADHD market. Datamonitor believes Shire will market Intuniv as a second-line treatment option, due to clinical data demonstrating inferior efficacy to stimulant treatments, putting it in direct competition with Strattera.

The publication of a US government-sponsored study reporting an association between ADHD treatments and sudden unexplained death among pediatrics will reignite the debate over the safety of ADHD drugs in children. The media coverage will cause some parents in the US to choose to discontinue or not begin stimulant therapy for their children.

Key reasons to purchase this title

Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2009 to 2018.

Quantify the current size of the seven major markets and the trends in the rest of the world.

Assess the impact of events, such as patent expiries and new product launches, on the future sales of key brand name ADHD products.

For more information visit http://www.researchandmarkets.com/research/3555aa/forecast_insight Source: Datamonitor

Keywords: , Health, Mental Health, Pediatrics, Pediatrics, ADHD, Adrenergic Agent, Adrenergic Uptake Inhibitor, Amphetamine, Attention Deficit Hyperactivity Disorder, Central Nervous System Stimulant, Developmental Disabilities, Dopamine, Drug Development, Drug Safety, Mental Health, Therapy, Treatment, Research and Markets Ltd.

This article was prepared by Anti-Infectives Week editors from staff and other reports. Copyright 2009, Anti-Infectives Week via NewsRx.com.